SEC filing summary
Entity and period: The supplied filing identifies the registrant as NanoAntibiotics, Inc., not BioVie Inc. It is a Form 10-Q for the three months ended September 30, 2015, the company’s fiscal first quarter. The unaudited financial statements compare the quarter with the three months ended September 30, 2014.
Business context and financial results
NanoAntibiotics describes itself as an early-stage biotechnology company developing broad-spectrum antibiotics, including candidates intended to target drug-resistant bacteria. Its candidates had been tested only in cell-based assays; animal efficacy and toxicity studies had not been conducted. The company reported no revenue in either comparison quarter.
| Metric | Quarter ended Sep. 30, 2015 | Prior-year quarter |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $54,627 | $58,890 |
| Operating loss | $54,627 | $58,890 |
| Net loss | $54,566 | $58,776 |
| Net loss per share, basic and diluted | $0.00 loss per share as presented | $0.00 loss per share as presented |
| Net cash used in operating activities | $1,965 | $14,717 |
At September 30, 2015, cash was $265,516 and total current assets were $266,016. Current liabilities were $372,811, consisting primarily of $363,319 in accrued payroll and $9,492 in accounts payable. The balance sheet therefore showed a $106,795 stockholders’ deficit. No debt balance is reported. Cash declined by $1,965 during the quarter; there were no investing or financing cash flows.
Changes and management outlook
- Net loss narrowed by $4,210 year over year, while operating expenses fell by $4,263. Research and development expense was $0, compared with $3,400 in the prior-year quarter; management said research and development was on hold while it pursued licensing rights.
- Cash was nearly unchanged from June 30, 2015 ($267,481), but current liabilities increased from $323,600, mainly due to accrued payroll rising from $322,950 to $363,319.
- Management said it lacked sufficient funds for the next 12 months and estimated it needed approximately $1 million in additional financing to fund its plans. Its proposed 12-month budget included $750,000 for research and development, $50,000 for corporate overhead, $50,000 for capital costs, and $150,000 for staffing.
- The company expected existing cash to last until June 30, 2016, but warned it might have to reduce or stop development, seek licensing or partnerships, sell assets, or cease operations if it could not raise capital. Management stated that these conditions raised substantial doubt about the company’s ability to continue as a going concern.
Risks, contingencies, and other notable items
- The company had no product revenue, limited drug-development experience, and no committed financing source. It cautioned that candidates might not be developed successfully or obtain regulatory approval.
- Management reported that disclosure controls and procedures were not effective as of September 30, 2015. It reported no material change in internal control over financial reporting during the quarter.
- A five-year office lease beginning January 2014 requires monthly payments of $357. The CEO/CFO employment agreement specified an annual salary of $150,000 and expired June 30, 2015; the filing says salaries would continue at that rate until a new agreement was reached.
- The company reported no material legal proceedings and no material off-balance-sheet arrangements. It disclosed 5 million potentially dilutive warrants, excluded from diluted loss per share because they were anti-dilutive.
Important facts for investors to verify
- Confirm the filing belongs to the intended company: the request metadata says BioVie Inc., while the filing names NanoAntibiotics, Inc.
- Verify current financing, cash runway, accrued payroll obligations, and whether the stated approximately $1 million funding need was met.
- Check the status of licensing discussions, research plans, and any animal studies or subsequent development milestones.
- Review subsequent disclosures on the going-concern uncertainty and remediation of ineffective disclosure controls.
- Confirm the status of the expired employment agreement, outstanding warrants, and any subsequent share issuance or financing.